Update of the clinical impact and issues surrounding Dofetilide (Tikosyn) therapy.
Friedman
Lyudmila
L
Department of Pharmacy Services, Tampa General Hospital, FL 33601-1289, USA. lfriedman@tgh.org
Alexander
Earnest
E
D000465:Algorithms; D000889:Anti-Arrhythmia Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000188:drug therapy*; D001282:Atrial Flutter / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D003422:Critical Care / Q000379:methods; D003663:Decision Trees; D004334:Drug Administration Schedule; D017277:Drug Approval; D004347:Drug Interactions; D016903:Drug Monitoring / Q000379:methods / Q000451:nursing; D004562:Electrocardiography; D006801:Humans; D024802:Nurse's Role; D018579:Patient Selection; D010627:Phenethylamines / Q000494:pharmacology / Q000627:therapeutic use*; D026902:Potassium Channel Blockers / Q000494:pharmacology / Q000627:therapeutic use*; D013449:Sulfonamides / Q000494:pharmacology / Q000627:therapeutic use*; D013686:Telemetry; D014481:United States; D014486:United States Food and Drug Administration
D000889:Anti-Arrhythmia Agents; D010627:Phenethylamines; D026902:Potassium Channel Blockers; D013449:Sulfonamides; C063533:dofetilide